Skip to main content

Artidis ends successful study

| News

Artidis ends successful study


Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.

The team of Artidis, a spin-off from the University of Basel (img: Artidis)

Artidis has developed an innovative nanomechanical biomarker for cancer diagnosis and therapeutic optimization using the company’s own platform. By merging various medical data, the platform aims to make diagnosis quicker and create personalized plans for cancer treatment. This platform and therefore also the biomarker have recently been investigated in the NANO study according to a press release from Artidis, with the primary endpoint of the study being met.

The endpoint was sensitivity, which is a percentage showing the number patients for whom a disease was actually recognized. The primary endpoint of the NANO study was 90 percent, and a value of 96 percent was achieved. As such, the study endpoint was met, meaning that the nanomechanical biomarkers can be used for breast cancer biopsy in a clinical setting. The data from 520 patients were gathered in the analysis.

Marija Plodinec, CEO of Artidis, is quoted in the article: “We are very pleased with the excellent results from this first prospective study conducted in Switzerland.” With this having proven the clinical benefit of the nanomechanical biomarker, she goes on to add: “We are convinced that this brings us one step closer to providing patients undergoing a biopsy procedure with a same day diagnosis.”

Artidis is a spin-off from a research group at the University of Basel and the Swiss Nanoscience Institute. Artidis has already taken part in the Venture Mentoring Program run by the investment and innovation promotion agency Basel Area Business & Innovation. The NANO study was conducted at the University Hospital Basel Breast Care Centre and the University of Basel Biozentrum.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.